Pharmaceutical Coalition for Patient Access v. United States

CourtCourt of Appeals for the Fourth Circuit
DecidedJanuary 23, 2025
Docket24-1230
StatusPublished

This text of Pharmaceutical Coalition for Patient Access v. United States (Pharmaceutical Coalition for Patient Access v. United States) is published on Counsel Stack Legal Research, covering Court of Appeals for the Fourth Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Pharmaceutical Coalition for Patient Access v. United States, (4th Cir. 2025).

Opinion

USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 1 of 30

PUBLISHED

UNITED STATES COURT OF APPEALS FOR THE FOURTH CIRCUIT

No. 24-1230

PHARMACEUTICAL COALITION FOR PATIENT ACCESS,

Plaintiff – Appellant,

v.

UNITED STATES OF AMERICA; DEPARTMENT OF HEALTH AND HUMAN SERVICES; OFFICE OF THE INSPECTOR GENERAL, U.S. Department of Health and Human Services; CHRISTI A. GRIMM, In Her Official Capacity as Inspector General of the United States Department of Health and Human Service; XAVIER BECERRA, In his official capacity as United States Secretary of the Department of Health and Human Services,

Defendants – Appellees.

Appeal from the United States District Court for the Eastern District of Virginia, at Richmond. Roderick Charles Young, District Judge. (3:22-cv-00714-RCY)

Argued: October 30, 2024 Decided: January 23, 2025

Before DIAZ, Chief Judge, KING, Circuit Judge, and Louise W. FLANAGAN, United States District Judge for the Eastern District of North Carolina, sitting by designation.

Affirmed by published opinion. Judge Flanagan wrote the opinion, in which Chief Judge Diaz and Judge King joined.

ARGUED: Paul J. Zidlicky, SIDLEY AUSTIN, LLP, Washington, D.C., for Appellant. Daniel Lee Winik, UNITED STATES DEPARTMENT OF JUSTICE, Washington, D.C., for Appellees. ON BRIEF: William A. Sarraille, PHARMACEUTICAL COALITION USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 2 of 30

FOR PATIENT ACCESS, Washington, D.C.; Madeleine Joseph, SIDLEY AUSTIN LLP, Washington, D.C., for Appellant. Brian M. Boynton, Principal Deputy Assistant Attorney General, Michael S. Raab, Charles W. Scarborough, Civil Division, UNITED STATES DEPARTMENT OF JUSTICE, Washington, D.C.; Jessica D. Aber, United States Attorney, OFFICE OF THE UNITED STATES ATTORNEY, Richmond, Virginia, for Appellees.

2 USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 3 of 30

FLANAGAN, District Judge:

In this appeal, Pharmaceutical Coalition for Patient Access (the “Coalition”), a

charitable organization involving a group of drug manufacturers, challenges an unfavorable

advisory opinion issued by the Office of the Inspector General for the United States

Department of Health and Human Services (the “Inspector General”), and the district

court’s decision below declining to disturb that opinion. We find no error in the district

court’s rulings and so affirm.

I.

Interaction between the Anti-Kickback Statute, 42 U.S.C. § 1320a-7b, and the

Coalition’s proposed patient assistance program to Medicare beneficiaries is at the heart of

the dispute. We begin with a brief overview of Medicare, the Coalition’s program, and the

Anti-Kickback Statute as pertinent to this case.

Medicare has four parts. Relevant here is Part D, which generally covers outpatient

prescription drugs in conjunction with beneficiary co-pays. A Part D beneficiary is

responsible for an initial deductible, and then enters various coverage thresholds, where

the beneficiary is responsible for a 25% co-pay until reaching a “catastrophic coverage”

threshold. At that point, the beneficiary is responsible only for a 5% co-pay, but with no

dollar figure cap. 1

1 Subsequent changes in the law altered some of these numbers, but these figures governed during the events of this case, and the subsequent changes make no difference to the legal issues now before the court. See J.A. 159.

3 USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 4 of 30

As a result, some Part D beneficiaries are unable to access medically necessary

oncology drugs due to significant out-of-pocket costs. J.A. 165. According to the advisory

opinion, this structure exposes beneficiaries to the economic effects of drug pricing,

thereby discouraging drug manufacturers from setting excessive prices. See J.A. 173–74.

The Coalition conceived of a patient assistance program to help Part D beneficiaries

afford oncology drugs. The program would subsidize a Part D beneficiary’s co-pays if he

or she had 1) a cancer diagnosis; 2) a household income between 150% and 350% of the

federal poverty line; 3) a prescription for a Part D oncology drug produced by a

participating manufacturer; and 4) initial approval for coverage for the drug through his or

her Part D plan. J.A. 96, 125. Participation in the program would be open to any

manufacturer of branded or generic oncology drugs reimbursed by Part D, and each

participating manufacturer would pay the Coalition for costs associated with the subsidies

the Coalition pays for that manufacturer’s own products (hereinafter the “funding

manufacturers”). See J.A. 95, 169–70, 172. In addition to these co-pay subsidies, the

Coalition would offer support for a cancer patient’s “additional medical needs,” and for

various initiatives to support cancer screening and research. J.A. 94.

The Anti-Kickback Statute prohibits, as pertinent here, “knowingly and willfully

offer[ing] or pay[ing] any remuneration” to “induce” an individual to purchase a federally

reimbursable healthcare product. 42 U.S.C. § 1320a-7b(b)(2).

The relevant part of the statute is as follows:

(2) Whoever knowingly and willfully offers or pays any remuneration (including any kickback, bribe, or rebate) directly or indirectly, overtly or covertly, in cash or in kind to any person to induce such person –

4 USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 5 of 30

(A) to refer an individual to a person for the furnishing or arranging for the furnishing of any item or service for which payment may be made in whole or in part under a Federal health care program, or

(B) to purchase, lease, order, or arrange for or recommend purchasing, leasing, or ordering any good, facility, service, or item for which payment may be made in whole or in part under a Federal health care program,

shall be guilty of a felony and upon conviction thereof, shall be fined not more than $100,000 or imprisoned for not more than 10 years, or both.

Id.

Given the statute’s criminal penalties, Congress also permitted parties to seek

advisory opinions from the Inspector General on whether a proposed program would

violate the statute. Id. § 1320a-7d(b). Advisory opinions bind the Department of Health

and Human Services and the requesting party. Id. § 1320a-7d(b)(4)(A).

In this case, the Coalition requested such an opinion January 25, 2022. The

Inspector General informed the Coalition that it had reached an unfavorable decision July

8, 2022, which would issue in the form of an advisory opinion if the Coalition did not

voluntarily withdraw its request. The Coalition declined. Thereafter, the advisory opinion

issued, which determined that the Coalition’s proposed program would fall within the

statute’s proscriptions if the required mens rea were present, on grounds that the Coalition

would pay remuneration in the form of subsidies to induce Part D beneficiaries to purchase

funding manufacturers’ drugs. According to the advisory opinion, the program was

“highly suspect” as an attempt to “sidestep” the Anti-Kickback Statute and Medicare Part

D, and would constitute grounds for sanctions if carried out. J.A. 174, 177.

5 USCA4 Appeal: 24-1230 Doc: 30 Filed: 01/23/2025 Pg: 6 of 30

The Coalition sued in the United States District Court for the Eastern District of

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Arkansas Best Corp. v. Commissioner
485 U.S. 212 (Supreme Court, 1988)
Chickasaw Nation v. United States
534 U.S. 84 (Supreme Court, 2001)
Barnhart v. Sigmon Coal Co.
534 U.S. 438 (Supreme Court, 2002)
Gomez-Perez v. Potter
553 U.S. 474 (Supreme Court, 2008)
United States v. Williams
553 U.S. 285 (Supreme Court, 2008)
Ali v. Federal Bureau of Prisons
552 U.S. 214 (Supreme Court, 2008)
Skilling v. United States
561 U.S. 358 (Supreme Court, 2010)
United States v. William H. Zacher
586 F.2d 912 (Second Circuit, 1978)
United States v. Larry E. Jennings, Sr.
160 F.3d 1006 (Fourth Circuit, 1998)
United States v. Charles R. Dauray
215 F.3d 257 (Second Circuit, 2000)
Christopher v. Smithkline Beecham Corp.
132 S. Ct. 2156 (Supreme Court, 2012)
Adoptive Couple v. Baby Girl
133 S. Ct. 2552 (Supreme Court, 2013)
Robert Ranta v. Thomas Gorman
721 F.3d 241 (Fourth Circuit, 2013)
Angelex LTD. v. United States
723 F.3d 500 (Fourth Circuit, 2013)

Cite This Page — Counsel Stack

Bluebook (online)
Pharmaceutical Coalition for Patient Access v. United States, Counsel Stack Legal Research, https://law.counselstack.com/opinion/pharmaceutical-coalition-for-patient-access-v-united-states-ca4-2025.